Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference

Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference




Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Canaccord Genuity Virtual 41st Annual Growth Conference, held August 12-13, 2021. Apnimed’s presentation is scheduled for Thursday, August 12th at 4:00pm EDT. Management will be available August 12-13 throughout the conference for virtual one-on-one.

Investors interested in arranging a meeting with the Company’s management during the conference should contact the Canaccord Genuity conference coordinator.

Webcast Link:

A live webcast of Apnimed’s presentation session will be available in the Events section of the Company’s website at https://apnimed.com/events/ or can be accessed via the following link:

Link to webcast: https://wsw.com/webcast/canaccord60/apni/2436896

An archived replay will be available for approximately 30 days following the conference.

About Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is one of the most common and serious sleep disorders and is estimated to affect more than 25 million Americans, though underdiagnosis continues to be a serious problem. OSA is characterized by partial or complete upper airway closure that occurs during sleep, which often leads to poor sleep, and in the long-term has been shown to exacerbate hypertension, diabetes, cardiovascular disease, and stroke. Additionally, OSA can impair work productivity, reduce functional ability, and lower quality of life.

Sleep-related muscular relaxation driven by the central nervous system is the key neurologic mechanism leading to OSA. In patients with OSA, sleep onset leads to a reduction in neuromuscular control of the upper airway and a corresponding relaxation of the upper airway dilator muscles. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but many patients are dissatisfied with these mechanical nighttime devices and fewer than half are compliant long-term, leaving a significant population untreated, undertreated, and at risk.

About Apnimed

Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with Obstructive Sleep Apnea will benefit from treatment with a safe and effective oral medication. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. The drug is delivered as a convenient once-daily at bedtime. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at apnimed.com

Contacts

Media:
Courtney Heath

ScientPR

courtney@scientpr.com
617-872-2462

Investor:
Wendy Gabel

Kendall IR

wgabel@kendallir.com
617-914-0008